“Safety and Adverse Events of Special Interest in 825 Adults With Atopic Dermatitis Receiving Up to 12 Months of Tralokinumab Treatment in a Real-World Setting”. 2026. SKIN The Journal of Cutaneous Medicine 10 (2): s730. https://doi.org/10.25251/7mx6d484.